Biologics for psoriasis during the COVID-19 pandemic

In the news: Baseline body surface area may drive optimal baricitinib responses Avoiding atopic dermatitis triggers easier said than done * * * * * * * * * Psoriasis patients often have additional comorbidities that put them at higher risk for developing COVID-19. In this episode, Candrice R. Heath, MD (@DrCandriceHeath), talks to Mark G. Lebwohl, MD, about the benefits of continuing biologic therapies for psoriasis during the COVID-19 pandemic. They discuss findings from registry data in Italy and New York City and how the data have impacted the latest guidelines for treatment. “The [National Psoriasis Foundation COVID-19 Task Force] has come out with a recommendation that strongly encourages patients on biologics to take [the COVID-19] vaccination and to not interrupt your biologic therapy,” Dr. Lebwohl explains. They also discuss how dermatologists can counsel patients about the safety of biologics so they feel comfortable continuing treatment during the pandemic. * * * Hosts: Nick Andrews; Candrice R. Heath, MD (Temple University Hospital, Philadelphia) Guests: Mark G. Lebwohl, MD (Icahn School of Medicine at Mount Sinai, New York) Disclosures: Dr. Heath reports no conflict of interest. Dr. Lebwohl is an employee of Mount Sinai and has received research funds and consulted with numerous pharmaceutical companies. Show notes by: Alicia Sonners, Melissa Sears * * * You can find more of our podcasts at http://www.mdedge.com/podcasts Email the show: [email protected] Interact with us on Twitter: @MDedgeDerm

Release date

Lydbog: 14. januar 2021